J&J's HIV vaccine fails in sub-Saharan Africa trial | The Guardian Nigeria News - Nigeria and World News

  • 📰 GuardianNigeria
  • ⏱ Reading Time:
  • 19 sec. here
  • 2 min. at publisher
  • 📊 Quality Score:
  • News: 11%
  • Publisher: 94%

Health Health Headlines News

Health Health Latest News,Health Health Headlines

Johnson & Johnson's highly anticipated HIV vaccine failed to demonstrate adequate protection in a clinical trial involving more than 2,600 young women in sub-Saharan Africa, the company and US health authorities said Tuesday.

In this file photo taken on August 28, 2019 the entry sign to the Johnson & Johnson campus shows their logo in Irvine, California. – Four drugmakers, including Johnson & Johnson, went on trial April 19, 2021, over claims they helped fuel the deadly opioid epidemic in the United States through deceptive marketing that downplayed the risks of addiction.

But the company will continue a parallel trial involving men who have sex with men and transgender individuals that is taking place in the Americas and Europe, where vaccine composition differs and so do the prevalent HIV strains. The J&J vaccine uses similar adenovirus technology to its Covid-19 vaccine, and was delivered with four vaccinations over a year.

 

Thank you for your comment. Your comment will be published after being reviewed.
Please try again later.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

 /  🏆 1. in HEALTH

Health Health Latest News, Health Health Headlines